OXTELLAR Drug Patent Profile
✉ Email this page to a colleague
When do Oxtellar patents expire, and what generic alternatives are available?
Oxtellar is a drug marketed by Supernus Pharms and is included in one NDA. There are eleven patents protecting this drug.
The generic ingredient in OXTELLAR is oxcarbazepine. There are twenty-one drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oxtellar
A generic version of OXTELLAR was approved as oxcarbazepine by GLENMARK PHARMS LTD on October 9th, 2007.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for OXTELLAR?
- What are the global sales for OXTELLAR?
- What is Average Wholesale Price for OXTELLAR?
Summary for OXTELLAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for OXTELLAR |
| DailyMed Link: | OXTELLAR at DailyMed |
US Patents and Regulatory Information for OXTELLAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-003 | Oct 19, 2012 | AB | RX | Yes | Yes | 8,617,600 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-003 | Oct 19, 2012 | AB | RX | Yes | Yes | 11,166,960 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-003 | Oct 19, 2012 | AB | RX | Yes | Yes | 11,896,599 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-003 | Oct 19, 2012 | AB | RX | Yes | Yes | 7,722,898 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
